Pre-Conference Workshop Day Agenda
Pre-Conference Workshop Day
Tuesday 25th March 2025
9:00 am Workshop A
Unlocking Strategies for Target Selection in Novel Conjugated Drugs
Synopsis
Selecting the right target is undeniably important for novel conjugate drugs as it plays into the efficacy, toxicity profile, and therapeutic window, ultimately determining whether this new modality is worth pursuing. Join this in-depth workshop to explore advanced strategies in target selection for the development of cutting-edge conjugated drugs, for novel targets as well as previously validated ones. Gain insights into identifying and validating optimal targets to improve efficacy, safety, and clinical outcomes.
Join this workshop to:
- Explore novel target identification for bispecific ADCs to enhance therapeutic selectivity and reduce off-target toxicity whilst getting the desired level of immune engagement
- Balance sufficient tumor cell expression without overexpression that limits penetration into large or solid tumors
- Discover the wider target space for degrader-antibody conjugates and explore the rationale behind target selection for well-matched antibody and protein of interest targets
- Develop antibody degrader conjugates with innovative approaches to selecting degradation targets, ensuring efficient and selective protein degradation
- Consider novel targets for peptide drug conjugates for improved stability, potency, as well as internalization into cells and crossing the BBB
- Address challenges in target validation and determining the most suitable biomarkers for guiding conjugated drug development
12:00 pm Networking Lunch Break
1:00 pm Workshop B
Design Considerations for Optimizing Pharmacokinetic Profiles in Novel Conjugated Drugs
Synopsis
Achieving a desirable efficacy and toxicity profile can be crucial for dose optimization, costeffectiveness and can ultimately determine whether a novel conjugate drug is worth investing in. This workshop will delve into how novel formats—such as peptide drug conjugates (PDCs) or bispecific ADCs, or novel payloads with different mechanism of actions, such as antibody degrader conjugates (AbDCs), or alternative linker or conjugation technology can improve the therapeutic outcomes of drug conjugates
Join this workshop to:
- Review case studies of recent clinical translation in conjugated drugs, discussing how pharmacokinetic (PK), pharmacodynamic (PD) endpoints can determine the key drivers of the efficacy and safety profiles of drug conjugates.
- Discuss the role and contribution of different components of drug conjugate (formats, linker-payload, and conjugation types) in overall stability and PK/PD attributes and targeted delivery of drug conjugates.
- Analyze the PK/PD, safety and efficacy endpoints across approved and advanced drug conjugates to gage the efficiency of the current ADC design in expanding the therapeutic window.
- Determine how novel formats, linker and conjugation technology, novel payloads and Drugto-Antibody Ration (DAR) can improve the efficiency of targeted delivery of next generation drug conjugates